The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.
Face2Face Africa on MSN3d
White model who injected skin to become Black reveals plans to ‘move to Africa’A white model who had a subcutaneous injection to become black has revealed her intentions of moving to Africa in the next ...
AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...
If you're wondering how to change your skin care routine (and if you should), here's what dermatologist Dr Shammi Theesan ...
As people get out to clean up their yards, either getting it ready for spring or cleaning up after a spring storm, they often ...
The greater the number of risk factors in patients with cutaneous squamous cell carcinoma, the higher the likelihood of poor ...
An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.
Breaking down the best injectables to consider for more youthful skin, from Botox to polynucleotides and Profhilo.
The following is a summary of “Effect of spesolimab on sustained disease control in patients with generalized pustular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback